ATRA Share Price Performance
US$15.63
7.79 (99.36%)
Price US$15.63
Share PriceUS$15.63
There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues Despite A 25% Share Price Rise
Aug 13
Atara Biotherapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
ATRA Community Narratives
There are no narratives available yet.
Atara Biotherapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.83
- Gross Margin
- 2.94%
- Net Profit Margin
- 3.07%
- Debt/Equity Ratio
- 0%
Atara Biotherapeutics, Inc. Competitors
Snowflake Analysis
About ATRA
- Founded
- 2012
- Employees
- 38
- CEO
- WebsiteView website
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 1.1%
- 3 Months: 8.9%
- 1 Year: 18.9%
- Year to Date: 15.1%
The market has climbed 1.1% in the last 7 days, lead by the Information Technology sector with a gain of 1.9%. As for the past 12 months, the market is up 19%. Looking forward, earnings are forecast to grow by 15% annually. Market details ›